ArticleThe pharmacogenomics journal2010
Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines.
Article in The pharmacogenomics journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Pooled it
- Pooled it
- Article
- Extensive epigenetic and transcriptomic variability between genetically identical human B-lymphoblastoid cells with implications in pharmacogenomics research.Scientific reports · 2019Article
- Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.Current oncology reports · 2018Review
- Article
- Comparable impediment of cognitive function in female and male rats subsequent to daily administration of haloperidol after traumatic brain injury.Experimental neurology · 2017Article
- Human iPSC-derived neurons and lymphoblastoid cells for personalized medicine research in neuropsychiatric disorders.Dialogues in clinical neuroscience · 2016Review
- MicroRNA biogenesis and cellular proliferation.Translational research : the journal of laboratory and clinical medicine · 2015Article
- Reprogramming LCLs to iPSCs Results in Recovery of Donor-Specific Gene Expression Signature.PLoS genetics · 2015Article
- Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study.Environmental health perspectives · 2015Article
- Molecular insight into thiopurine resistance: transcriptomic signature in lymphoblastoid cell lines.Genome medicine · 2015Article
- Genomic architecture of pharmacological efficacy and adverse events.Pharmacogenomics · 2014Review
- Functional analysis and molecular characterization of spontaneously outgrown human lymphoblastoid cell lines.Molecular biology reports · 2014Article
- The impact of microRNA expression on cellular proliferation.Human genetics · 2014Article
- Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines.Pharmacogenomics · 2014Article
- Genetic variation is the major determinant of individual differences in leukocyte endothelial adhesion.PloS one · 2014Article
- Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs.Journal of molecular neuroscience : MN · 2013Article
- Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Publicly available genetic and expression data on lymphoblastoid cell lines (LCLs) make them a unique resource for understanding the genetic underpinnings of pharmacological outcomes and disease. LCLs have been used for pharmacogenomic discovery and validation of clinical findings associated with drug response. However, variation in cellular growth rate, baseline Epstein-Barr virus (EBV) copy number and ATP levels can all be confounders in such studies. Our objective is to better define confounding variables that affect pharmacological end points in LCLs. To this end, we evaluated the effect of these three variables on drug-induced cytotoxicity in LCLs. The drugs evaluated included daunorubicin, etoposide, carboplatin, cisplatin, cytarabine, pemetrexed, 5'-deoxyfluorouridine, vorinostat, methotrexate, 6-mercaptopurine, and 5-fluorouracil. Baseline ATP or EBV copy number were not significantly correlated with cellular growth rate or drug-induced cytotoxicity. In contrast, cellular growth rate and drug-induced cytotoxicity were significantly, directly related for all drugs except vorinostat. Importantly, cellular growth rate is under appreciable genetic influence (h²=0.30-0.39) with five suggestive linkage regions across the genome. Not surprisingly, a percentage of SNPs that significantly associate with drug-induced cytotoxicity also associate with cellular growth rate (P ≤ 0.0001). Studies using LCLs for pharmacologic outcomes should therefore consider that a portion of the genetic variation explaining drug-induced cytotoxicity is mediated via heritable effects on growth rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.